Propionic Acid

Propionic Acid

SCHEMBL17646231

CC(CC(O)CO)C(=O)O.CCC(=O)O.CCC(=O)O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.42
CYP1A2 P05177 1/20 0.40
NAALAD2 Q9Y3Q0 3/20 0.39
FOLH1 Q04609 2/20 0.39
ENPEP Q07075 2/20 0.39
OR51E2 Q9H255 1/20 0.36
GABRR1 P24046 2/20 0.35
TP53 P04637 1/20 0.35
FFAR4 Q5NUL3 1/20 0.33
ACE2 Q9BYF1 1/20 0.33
FFAR1 O14842 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL27738326 1.00 FFAR3 (0.42) FFAR3CYP1A2NAALAD2FOLH1ENPEP
SCHEMBL4751297 0.91 NAALAD2 (0.45) CYP1A2NAALAD2FOLH1ENPEPOR51E2
Ammonia Solution, Strong SCHEMBL7895146 0.89 NAALAD2 (0.43) CYP1A2NAALAD2FOLH1ENPEPOR51E2
Ethylene Glycol SCHEMBL15645227 0.87 NAALAD2 (0.42) CYP1A2NAALAD2FOLH1ENPEPOR51E2
Isobutanol SCHEMBL31333080 0.81 FFAR3 (0.43) FFAR3CYP1A2NAALAD2FOLH1ENPEP
Glycerin SCHEMBL30749460 0.79 FFAR3 (0.59) FFAR3OR51E2GABRR1FFAR4FFAR1
Glycerin SCHEMBL8830214 0.79 FFAR3 (0.59) FFAR3OR51E2GABRR1FFAR4FFAR1
Glycerin SCHEMBL274755 0.79 FFAR3 (0.59) FFAR3OR51E2GABRR1FFAR4FFAR1
Glycerin SCHEMBL78123 0.79 FFAR3 (0.59) FFAR3OR51E2GABRR1FFAR4FFAR1
Glycerin SCHEMBL30494639 0.79 FFAR3 (0.59) FFAR3OR51E2GABRR1FFAR4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204358-B1 CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2018-09-19 EP disclosed
EP-3204358-A1 CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2017-08-16 EP disclosed
US-9701639-B2 Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-07-11 US disclosed
WO-2016057730-A1 CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR STROHMEIER MARK (US) 2016-04-14 WO disclosed
US-20160096807-A1 CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160096807-A1 CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, CLIC1, CLIC4 FFAR3 507/4885CYP1A2 4729/4885NAALAD2 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.